Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to see if higher doses of imatinib mesylate
(Gleevec, STI571) can improve chronic myelogenous leukemia (CML) in chronic phase.